Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
Aclaris Therapeutics provided an update on its clinical programs, highlighting positive top-line results from the Phase Ia trial of its lead candidate ATI-052 and plans to advance ATI-2138 into a Phase IIb trial for Lichen Planus. The company emphasized the safety and tolerability profile of ATI-052 and its potential in autoimmune diseases. Executives outlined upcoming milestones and development timelines for both bispecific antibody candidates. The update was presented during a conference call with investors and analysts.
- ▪Aclaris Therapeutics reported positive full top-line results from the Phase Ia trial of ATI-052, demonstrating safety and tolerability in healthy volunteers.
- ▪The company plans to advance its candidate ATI-2138 into a Phase IIb clinical trial for the treatment of Lichen Planus.
- ▪ATI-052 and ATI-2138 are part of Aclaris’s lead bispecific antibody pipeline targeting autoimmune and inflammatory diseases.
- ▪The clinical update was shared in a conference call on April 28, 2026, with slides made available via webcast and the company’s investor relations website.
- ▪No serious adverse events were reported in the ATI-052 Phase Ia trial, supporting its progression into further clinical development.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895275-aclaris-therapeutics-inc-acrs-discusses-clinical-program-update-and-progress-of-lead"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
